When the best time is launching Japanese encephalitis vaccination programs in Hong Kong – A simple decision model for policy makers

Lok Yin Chan, Pui Hong Chung

The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Dear editor,

Using Japanese encephalitis (JE) as an example, we developed a decision making model for policy makers deciding the best time launching relevant vaccination programs by comparing the risk and benefit. Data of an inactivated Vero cell-derived vaccine, IXIARO®, and a most recent Hong Kong seroprevalence survey in 2004 are used in the analysis[1,2].

Risk of vaccinations (RV) is defined as serious vaccine associated complication rate that is multiplying rate of serious adverse events following immunization and recommended dosages of IXIARO®.

Benefit of vaccinations (BV) is defined as protection rate against lethal JE infections among vaccine responders that is multiplying seropositivity rates, rate of encephalitis among JE infections and immunogenicity of IXIARO®.

Agresti-Coull interval and Modified Wilson interval are used to determine the 95% confidence interval of BVs in the scale of 10⁻⁵ and those equal to zero respectively[3]. A sensitivity analysis on immunogenicity of IXIARO® is also performed.

As shown in Table 1, general outpatient clinic patients were representing general public and the other three populations were representing potential high risk groups due to their proximity of local cases and animal reservoirs, namely pigs and water birds[2]. And 95% confidence intervals of RV and BV overlap with each other in all populations. Therefore, RV is statistical insignificantly different from BVs among all populations.

Overall, we conclude that neither universal nor target populations JE vaccination programs should be launched in the given situations which matched with the decision made by Centre for Health Protection in 2004[2]. More importantly, this methodology is applicable to all other vaccine-preventable infectious diseases.

Conflict of interest statement

We declare that we have no conflict of interest.

References


Table 1
Risk-benefit comparison of Japanese encephalitis vaccination in Hong Kong.

<table>
<thead>
<tr>
<th>Population groups</th>
<th>No. of specimens</th>
<th>Risk of vaccination per 100 000 vaccine recipients (95% confidence interval)</th>
<th>Benefit of vaccination per 100 000 people (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General outpatient clinic patients</td>
<td>1190</td>
<td>3.20 (0.69–9.56)</td>
<td>9.41 (4.73–17.93)</td>
</tr>
<tr>
<td>Neighboring residents of JE cases</td>
<td>558</td>
<td>5.73 (2.23–13.07)</td>
<td>7.08 (3.12–14.88)</td>
</tr>
<tr>
<td>Pig farmers and abattoir workers</td>
<td>51</td>
<td>0.00 (0.00–3.69)</td>
<td>0.00 (0.00–3.69)</td>
</tr>
<tr>
<td>Mai Po local residents and workers</td>
<td>48</td>
<td>8.33 (3.98–16.53)</td>
<td>8.00 (3.75–16.09)</td>
</tr>
</tbody>
</table>

*Corresponding author: Pui Hong Chung, Room 419, Jockey Club School of Public Health and Primary Care, Prince of Wales Hospital, Hong Kong, China. Tel: (852) 93133169 Fax: (852) 21457489 E-mail address: chungpuihong@cuhk.edu.hk

Article history:
Received 8 Dec 2016
Accepted 15 Feb 2017
Available online 13 May 2017

©2017 by the Asian Pacific Journal of Tropical Disease. All rights reserved.